Literature DB >> 31966017

Practical considerations for the integration of subcutaneous targeted therapies into the oncology clinic.

Angela Boudreau1.   

Abstract

The oncology clinic is changing, with an increasing number of cancer therapies becoming available as formulations for subcutaneous (SC) injection. Using targeted therapies, such as alemtuzumab, bortezomib, rituximab or trastuzumab, via SC injection can be advantageous for patients, healthcare professionals, and healthcare systems. However, their use can also present challenges, and nurses have a unique opportunity to positively influence the integration of SC agents in the clinic. This article summarizes practical suggestions for optimal administration of SC targeted therapies, and provides pragmatic considerations for managing the change process related to their adoption.
© 2019 Canadian Association of Nurses in Oncology (CANO).

Entities:  

Year:  2019        PMID： 31966017      PMCID： PMC6970019     

Source DB:  PubMed          Journal:  Can Oncol Nurs J        ISSN： 1181-912X


  14 in total

Review 1.  What's all the buzz about change management?

Authors:  Janet Davidson
Journal:  Healthc Manage Forum       Date:  2015-04-01

Review 2.  A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma.

Authors:  D MacDonald; T Crosbie; A Christofides; W Assaily; J Wiernikowski
Journal:  Curr Oncol       Date:  2017-02-27       Impact factor: 3.677

Review 3.  A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.

Authors:  S Dent; C Ammendolea; A Christofides; S Edwards; D Incekol; B Pourmirza; S Kfoury; B Poirier
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

4.  Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Authors:  Stephan Stilgenbauer; Thorsten Zenz; Dirk Winkler; Andreas Bühler; Richard F Schlenk; Silja Groner; Raymonde Busch; Manfred Hensel; Ulrich Dührsen; Jürgen Finke; Peter Dreger; Ulrich Jäger; Eva Lengfelder; Karin Hohloch; Ulrike Söling; Rudolf Schlag; Michael Kneba; Michael Hallek; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

5.  Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

Authors:  Jeanette Lundin; Eva Kimby; Magnus Björkholm; Per-Anders Broliden; Fredrik Celsing; Viktoria Hjalmar; Lars Möllgård; Peppy Rebello; Geoff Hale; Herman Waldmann; Håkan Mellstedt; Anders Osterborg
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

6.  Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.

Authors:  X Pivot; S Verma; L Fallowfield; V Müller; M Lichinitser; V Jenkins; A Sánchez Muñoz; Z Machackova; S Osborne; J Gligorov
Journal:  Eur J Cancer       Date:  2017-09-28       Impact factor: 9.162

7.  Subcutaneous Administration of Monoclonal Antibodies in Oncology.

Authors:  C Jackisch; V Müller; C Maintz; S Hell; B Ataseven
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-04       Impact factor: 2.915

8.  A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.

Authors:  Erwin De Cock; Xavier Pivot; Nik Hauser; Sunil Verma; Persefoni Kritikou; Douglas Millar; Ann Knoop
Journal:  Cancer Med       Date:  2016-01-25       Impact factor: 4.452

Review 9.  Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses.

Authors:  Jasmine R Martin; Nancy L Beegle; Yanyan Zhu; Ellen M Hanisch
Journal:  J Adv Pract Oncol       Date:  2015-07-01

Review 10.  Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.

Authors:  Andrew Davies; Claude Berge; Axel Boehnke; Anjum Dadabhoy; Pieternella Lugtenburg; Simon Rule; Mathias Rummel; Christine McIntyre; Rodney Smith; Xavier Badoux
Journal:  Adv Ther       Date:  2017-10-05       Impact factor: 3.845
View more
  1 in total

1.  Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Authors:  Enriqueta Felip; Mauricio Burotto; Zanete Zvirbule; Luis A Herraez-Baranda; Pascal Chanu; Smita Kshirsagar; Vidya Maiya; Phyllis Chan; Emanuela Pozzi; Mathilde Marchand; Marion Monchalin; Kunihiko Tanaka; Nadia Tosti; Bei Wang; Eleonora Restuccia
Journal:  Clin Pharmacol Drug Dev       Date:  2021-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.